Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
GPCR
GPCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GPCR News
Structure Therapeutics' GLP-1 Drug Shows Promising Potential
Feb 05 2026
Fool
Structure Therapeutics Emerges as Potential Takeover Target for Big Pharma
Jan 30 2026
seekingalpha
Structure Therapeutics Advances Aleniglipron into Phase 3 Trials Following Novo Nordisk's Oral GLP-1 Launch
Jan 23 2026
Benzinga
Eli Lilly and Novo Nordisk Drive Diversification in Obesity Drug Market
Jan 23 2026
CNBC
Structure Therapeutics Advances Weight-Loss Pill with 11.3% Weight Loss in 36 Weeks
Jan 15 2026
Benzinga
Viking Therapeutics CEO Highlights Broad Strategic Interest in Weight-Loss Drug Deals, Shares Surge 17%
Jan 14 2026
stocktwits
FMR LLC Sells 52,356 Shares of Structure Therapeutics for Approximately $3.8 Million
Jan 13 2026
Fool
Structure Therapeutics (GPCR) Sells Over 50,000 Shares for Nearly $4 Million
Jan 13 2026
NASDAQ.COM
Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
Jan 13 2026
Benzinga
Anticipate a Hectic Year for Obesity Medications with New Pills Launching
Jan 12 2026
Barron's
Structure Therapeutics Reports Positive Phase 2 Data for Aleniglipron, Stock Soars
Jan 11 2026
NASDAQ.COM
Structure Therapeutics Reports Strong Mid-Stage Data for Aleniglipron, Boosting 2025 Outlook
Jan 11 2026
Fool
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
Dec 31 2025
Benzinga
Structure Therapeutics Closes $747.5 Million Upsized Public Offering
Dec 11 2025
Newsfilter
Structure Therapeutics Prices $650 Million Upsized Public Offering
Dec 10 2025
Newsfilter
Structure Therapeutics Prices Upsized Public Offering at $650 Million
Dec 10 2025
Globenewswire
Show More News
